Hengrui Origin's Multi-Antigen Autologous Immune Cell Injection (MASCT-I) Receives IND Approval for New Solid Tumor Indication: Advanced Soft Tissue Sarcoma

MASCT-I isThe world's first clinically approved multi-target T-cell therapy product for solid tumors, This approval is for the expansion of indications. Currently targetingUrothelial CarcinomaThe clinical trial for the indications has entered phase II, with the first patient successfully enrolled on January 11, 2023. The study is being conducted in collaboration with 26 tertiary hospitals across China. According to the official website of Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd., this product targetsLiver CancerThe experiment has also entered phase one of clinical trials.

MASCT is the abbreviation for Multi-Antigen Autologous Immune Cell Injection.Autologous Immune Cell TherapyTechnical Product Series, FeaturingTargeting Solid Tumors, Multi-Targeting to Combat Tumor Heterogeneity, and Countering Immune EscapeThree major advantages. Its active components include mature autologous dendritic cells (DC cells) loaded with 15 tumor-associated antigens and autologous effector T lymphocytes (T cells) activated and expanded by the aforementioned DC cells. The two are used in sequential treatment, inTumor clearance in the body through cytotoxic actionIn addition, a portion of the multi-antigen-loaded DC cells were further co-cultured with the patient's peripheral blood mononuclear cells (PBMCs) to activate and expand tumor-specific T cells within the PBMCs, thereby...Obtaining a Large Number of Effector T Cells with Anti-Tumor Effects In VitroThese effector T cells are intravenously infused back into the patient's body, enter the tumor tissue through blood circulation, and further exert their tumor-killing effects.

In May 2023, Hengrui Yuanzheng's HRYZ-T101 injection was approved for clinical trials.The World's First TCR-T Product Targeting High-Frequency HLA in the Chinese Population, with patent authorization in both China and the US, as well as extensive PCT coverage, features a completely new TCR sequence and is aimed atFirst-in-class TCR-T Cell Therapy Product for Solid Tumor Innovative TargetsThis is due to the separation of TCR with optimal affinity from tumor patients who have benefited from MASCT's many years of clinical treatment, accumulating a large amount of TCR data based on Asian population HLA typing, and TCR products based on European and American population HLA typing haveSignificant AdvantagesThis may be the confidence that Hengrui has to "bet everything" in the cell therapy field.

Silent until it speaks, and when it speaks, it astonishes. Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd., which has had a bumper year in both regulatory approvals and financing, is actuallyHengrui's Long-Awaited Showcase of Achievements in Solid Tumor Cell TherapyHengrui Yuanzheng is currently the only company in which Hengrui has invested and laid out in the field of cell therapy. As early as 2015, Hengrui and Yuanzheng Cell jointly established Hengrui Yuanzheng.Sun Piaoyang Personally Takes the Helm as Chairman of Hengrui Yuanzheng, bringing together the old team and a group of doctors and professors to start anew, focusing on developing immunotherapy products, including the TCR-T cell therapy product HRYZ-T pipeline for solid tumors and the multi-target T cell therapy product MASCT pipeline, which is the main subject of this approval.

Currently, Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd. has collaborated with several leading hospitals in the oncology field to initiate registered clinical trials and investigator-initiated studies, securing a strong academic position while laying a solid foundation for future product commercialization.Clinical FoundationPreviously, Hengrui Yuanzheng invested 500 million yuan in Songjiang to build the company's Shanghai headquarters and a regional cell preparation center covering the Yangtze River Delta region, creating a high-end transformation platform for the research, development, and clinical application of immune cell therapy technology, providing a solid foundation for future product commercialization.Industrial FoundationBased on the above core advantages, Zijin Harbor Capital and others are optimistic about the potential of Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd. as a leading enterprise in the field of immunotherapy. They continue to invest in support of advancing the R&D pipelines of Hengrui Yuanzheng’s MASCT and TCR-T. Hengrui Yuanzheng completed this in May.Series C Financing Exceeds 200 Million Yuan。

Source: Yimaike